158 related articles for article (PubMed ID: 34568384)
1. Current Regulatory Requirements for Biosimilars in Six Member Countries of BRICS-TM: Challenges and Opportunities.
Rahalkar H; Sheppard A; Santos GML; Dasgupta C; Perez-Tapia SM; Lopez-Morales CA; Salek S
Front Med (Lausanne); 2021; 8():726660. PubMed ID: 34568384
[No Abstract] [Full Text] [Related]
2. Comparison of BRICS-TM Countries' Biosimilar Regulatory Frameworks With Australia, Canada and Switzerland: Benchmarking Best Practices.
Rahalkar H; Sheppard A; Salek S
Front Pharmacol; 2021; 12():711361. PubMed ID: 34434109
[No Abstract] [Full Text] [Related]
3. Challenges Faced by the Biopharmaceutical Industry in the Development and Marketing Authorization of Biosimilar Medicines in BRICS-TM Countries: An Exploratory Study.
Rahalkar H; Sheppard A; Lopez-Morales CA; Lobo L; Salek S
Pharmaceut Med; 2021 Jul; 35(4):235-251. PubMed ID: 34292558
[TBL] [Abstract][Full Text] [Related]
4. Biosimilar development and review process in the BRICS-TM countries: Proposal for a standardized model to improve regulatory performance.
Rahalkar H; Sheppard A; Salek S
Expert Rev Clin Pharmacol; 2022 Feb; 15(2):215-236. PubMed ID: 35078378
[TBL] [Abstract][Full Text] [Related]
5. Quality, Non-clinical and Clinical Considerations for Biosimilar Monoclonal Antibody Development: EU, WHO, USA, Canada, and BRICS-TM Regulatory Guidelines.
Rahalkar H; Cetintas HC; Salek S
Front Pharmacol; 2018; 9():1079. PubMed ID: 30364154
[No Abstract] [Full Text] [Related]
6. PDA Biosimilars Workshop Report (September 27-28, 2018)-Getting It Right the First Time for Biosimilar Marketing Applications.
Krause S; Lacana E; Welch J; Shapiro M; Downey C; Chung J; Zhou Q; Van Der Plas M; Depatie C; Ingram B; Srebalus-Barnes C; Polozova A; Rellahan B; Choi D; Burdick R; Stangler T; Shacter E
PDA J Pharm Sci Technol; 2019; 73(4):401-416. PubMed ID: 31004040
[TBL] [Abstract][Full Text] [Related]
7. Regulatory Information and Guidance on Biosimilars and Their Use Across Europe: A Call for Strengthened One Voice Messaging.
Barbier L; Mbuaki A; Simoens S; Declerck P; Vulto AG; Huys I
Front Med (Lausanne); 2022; 9():820755. PubMed ID: 35355594
[TBL] [Abstract][Full Text] [Related]
8. 'BRICS without straw'? A systematic literature review of newly emerging economies' influence in global health.
Harmer A; Xiao Y; Missoni E; Tediosi F
Global Health; 2013 Apr; 9():15. PubMed ID: 23587342
[TBL] [Abstract][Full Text] [Related]
9. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.
Ingrasciotta Y; Cutroneo PM; Marcianò I; Giezen T; Atzeni F; Trifirò G
Drug Saf; 2018 Nov; 41(11):1013-1022. PubMed ID: 29796832
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Good Review Practices of Countries Participating in the Southern African Development Community: Alignment and Strategies for Moving Forward.
Sithole T; Mahlangu G; Capote V; Sitoie T; Shifotoka S; Gaeseb J; Padayachee S; Sehloho T; Khea A; Fimbo A; Munkombwe Z; Mwale B; Salek S; Walker S
Front Med (Lausanne); 2021; 8():742181. PubMed ID: 34513893
[No Abstract] [Full Text] [Related]
11. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
Tomić S; Sucić AF; Martinac AI
Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
[TBL] [Abstract][Full Text] [Related]
12. Essential drugs production in Brazil, Russia, India, China and South Africa (BRICS): opportunities and challenges.
Ezziane Z
Int J Health Policy Manag; 2014 Dec; 3(7):365-70. PubMed ID: 25489593
[TBL] [Abstract][Full Text] [Related]
13. Quality Issues Identified During the Evaluation of Biosimilars by the European Medicines Agency's Committee for Medicinal Products for Human Use.
Cilia M; Ruiz S; Richardson P; Salmonson T; Serracino-Inglott A; Wirth F; Borg JJ
AAPS PharmSciTech; 2018 Feb; 19(2):489-511. PubMed ID: 29027130
[TBL] [Abstract][Full Text] [Related]
14. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
Ahmed I; Kaspar B; Sharma U
Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
[TBL] [Abstract][Full Text] [Related]
15. Mapping the tuberculosis scientific landscape among BRICS countries: a bibliometric and network analysis.
Castor K; Mota FB; da Silva RM; Cabral BP; Maciel EL; de Almeida IN; Arakaki-Sanchez D; Andrade KB; Testov V; Vasilyeva I; Zhao Y; Zhang H; Singh M; Rao R; Tripathy S; Gray G; Padayatchi N; Bhagwandin N; Swaminathan S; Kasaeva T; Kritski A
Mem Inst Oswaldo Cruz; 2020; 115():e190342. PubMed ID: 32187325
[TBL] [Abstract][Full Text] [Related]
16. Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency.
Collignon O; Koenig F; Koch A; Hemmings RJ; Pétavy F; Saint-Raymond A; Papaluca-Amati M; Posch M
Trials; 2018 Nov; 19(1):642. PubMed ID: 30454061
[TBL] [Abstract][Full Text] [Related]
17. Potential Regulatory and Commercial Environment for Biosimilars in Latin America.
Azevedo VF; Sandorff E; Siemak B; Halbert RJ
Value Health Reg Issues; 2012 Dec; 1(2):228-234. PubMed ID: 29702905
[TBL] [Abstract][Full Text] [Related]
18. Biosimilars: Practical Considerations for Pharmacists.
Stevenson JG; Popovian R; Jacobs I; Hurst S; Shane LG
Ann Pharmacother; 2017 Jul; 51(7):590-602. PubMed ID: 28176529
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Review Models and Approval Timelines of Countries Participating in the Southern African Development Community: Alignment and Strategies for Moving Forward.
Sithole T; Mahlangu G; Capote V; Sitoie T; Shifotoka S; Gaeseb J; Danks L; Nkambule P; Juma A; Fimbo A; Munkombwe Z; Mwale B; Salek S; Walker S
Front Med (Lausanne); 2021; 8():742200. PubMed ID: 34513894
[No Abstract] [Full Text] [Related]
20. Regulatory Perspective of International Agencies for Development of Biosimilar Products (Monoclonal Antibodies): An Overview.
Sharma A; Khante S; Mahadik KR; Gaikwad VL
Ther Innov Regul Sci; 2020 Sep; 54(5):965-977. PubMed ID: 31933180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
